The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters
The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters, a Randomised Placebo-controlled Double-blind Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Amanda Rao, PhD
- Phone Number: +61 414 488 559
- Email: amanda@rdcglobal.com.au
Study Contact Backup
- Name: David Briskey, PhD
- Phone Number: +61 421 784 077
- Email: d.briskey@uq.edu.au
Study Locations
-
-
Queensland
-
Newstead, Queensland, Australia, 4006
- RDC Clinical Pty Ltd
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged 18 years and above
- Self-reporting Stress
- Able to provide informed consent
- Agree not to change current diet and exercise program while enrolled in this trial
- Agree not to undertake another clinical trial while enrolled in this trial
Exclusion Criteria:
- Unstable or serious illness (e.g. Serious mood disorders, neurological disorders such as MS, kidney disease, liver disease, heart conditions, diabetes, thyroid gland dysfunction)*
- Current malignancy (excluding BCC) or chemotherapy and radiotherapy treatment for malignancy within the previous 2 years
- Receiving/prescribed coumadin (Warfarin), heparin, dalteparin, enoxaparin or other anticoagulation therapy
- Receiving treatment for anxiety, or taking supplements# for anxiety or sleep conditions such as saffron, valerian, etc.
- Active smokers, nicotine use, alcohol or drug (prescription or illegal substances) abuse
- Chronic past and/or current alcohol use (>14 alcoholic drinks week)
- Allergic to any of the ingredients in the active or placebo formula
- Known pregnant or lactating woman
- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
- Participants who have participated in any other related clinical study during the past 1 month
History of infection in the month prior to the study
An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
- Potential participants that are taking supplements that would result in their exclusion must wait a 4-week washout period prior to commencing the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Caralluma fimbriata
Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
|
Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
Other Names:
|
|
Placebo Comparator: Placebo comparator capsule - Microcrystalline cellulose
A comparator capsule taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
|
Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in stress as assessed by Perceived Stress Scale (PSS)
Time Frame: Baseline prior to commencement of study product, Week 4 and Week 8
|
Change in stress as assessed by Perceived Stress Scale (PSS) - Score range 0-40, Higher scores indicate higher perceived stress.
|
Baseline prior to commencement of study product, Week 4 and Week 8
|
|
Change in stress as assessed by Salivary Cortisol levels
Time Frame: Baseline prior to commencement of study product, Week 4 and Week 8
|
Change in stress as assessed by Salivary Cortisol levels through assay
|
Baseline prior to commencement of study product, Week 4 and Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in stress and mood as assessed by the Profile of Mood States (POMS) scale
Time Frame: Baseline prior to commencement of study product, Week 4 and Week 8
|
Change in stress as assessed by Profile of Mood States (POMS) scale - Six dimensions including Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment assessed ona five point scale ranging from "not at all" to "extremely".
|
Baseline prior to commencement of study product, Week 4 and Week 8
|
|
Change in stress and mood as assessed by The Depression, Anxiety Stress Scale -21 (DASS-21)
Time Frame: Baseline prior to commencement of study product, Week 4 and Week 8
|
Change in stress as assessed by DASS-21 - A set of three self-reported scales to measure emotional states of depression, anxiety and stress.
Each scale contains 7 items.
|
Baseline prior to commencement of study product, Week 4 and Week 8
|
|
Change in sleep as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline prior to commencement of study product, Week 4 and Week 8
|
Change in sleep as assessed by the Pittsburgh Sleep Quality Index (PSQI) which covers 7 domains with higher scores indicating poorer sleep quality.
|
Baseline prior to commencement of study product, Week 4 and Week 8
|
|
Change in sleep as measured by the Restorative Sleep Questionnaire (RSQ)
Time Frame: Baseline prior to commencement of study product, Week 4 and Week 8
|
Change in sleep as assessed by the Restorative Sleep Questionnaire (RSQ) which has 9 items scaled from 1-5.
Higher total scores indicate a more restorative sleep.
|
Baseline prior to commencement of study product, Week 4 and Week 8
|
|
Change in Neurotransmitters as assessed by pathology
Time Frame: Baseline prior to commencement of study product, Week 4 and Week 8
|
Change in neurotransmitters Serotonin, Dopamine, oxytocin, nor-epinephrine, adrenalin, glutamate and GABA as assessed by pathology
|
Baseline prior to commencement of study product, Week 4 and Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Amanda Rao, PhD, RDC Clinical Pty Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CARSTA-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.